New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain and work productivity.2-5 These new data from the DISCOVER-1, DISCOVER-2, and COSMOS studies are among 38 abstracts Janssen is presenting during the 2022 Annual European Congress for Rheumatology (EULAR) meeting taking place virtually and in-person in Copenhagen on June 1-4, 2022. TREMFYA is the first and only fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active psoriatic arthritis.6“Psoriatic arthritis is a complex disease, with a range of joint, skin, and axial symptoms. Patients need long-lasting therapies that can provide efficacy across these varied challenges,” said presenting study author Philip Mease, M.D., Swedish Medical Center/Providence St. Joseph Health and University of Washington in Seattle, Washington.d “These new data reinforce...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy & Immunology | Anemia | Anxiety | Arthritis | Autoimmune Disease | Babies | Babies Heart Conditions | Back Pain | Brain | Breastfed | Bronchitis | Canada Health | Cancer & Oncology | Cardiology | Cardiovascular | Chronic Pain | Clinical Trials | Cold Sores | Complementary Medicine | Depression | Disability | Eating Disorders & Weight Management | Economics | Emergency Medicine | Environmental Health | Food and Drug Administration (FDA) | Gastroenteritis | Gastroenterology | Genetics | Headache | Health Management | Heart | Herbs | Herpes | Hypertension | Infectious Diseases | Inflammatory Bowel Disease | Japan Health | Learning | Legislation | Marketing | Men | Migraine | Milk | Neurology | Neuroscience | Obesity | Pain | Perinatology & Neonatology | Pharmaceuticals | Politics | Postnatal Depression | Pregnancy | Profits and Losses | Psoriasis | Psoriatic Arthritis | Pulmonary Hypertension | Radiography | Respiratory Medicine | Rheumatology | Science | Skin | Study | Sweden Health | Tuberculosis | Ulcerative Colitis | Universities & Medical Training | University of Washington | Vaccines | Vitamins